Our results also revealed that SPRY2 expression is positively correlated with the sensitivity of the cancer cell lines to many MEK inhibitors from GDSC, suggesting that SPRY2 expression may be a predictive biomarker for the effectiveness of MEK kinase inhibitors. Here, SPRY2 is linked to cancer.